Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Parameswaran Hari

Showing results (81-90 of 255) with videos related to

Pageof 26
Sort By:
Cytotherapy|December 31, 2017
Closed-system manufacturing of CD19 and dual-targeted CD20/19 chimeric antigen receptor T cells using the CliniMACS Prodigy device at an academic medical centerFenlu Zhu, Nirav Shah, Huiqing Xu, et al.
Contemporary Clinical Trials Communications|April 27, 2018
Rationale and design of DUAL study: Doxycycline to Upgrade response in light chain (AL) amyloidosis (DUAL): A phase 2 pilot study of a two-pronged approach of prolonged doxycycline with plasma cell-directed therapy in the treatment of AL amyloidosisAnita D'Souza, Kathryn Flynn, Saurabh Chhabra, et al.
Cytotherapy|October 12, 2015
Hydroxyethyl starch as a substitute for dextran 40 for thawing peripheral blood progenitor cell productsFenlu Zhu, Sarah Heditke, Joanne Kurtzberg, et al.
Blood Reviews|December 1, 2014
All in the family: Clueing into the link between metabolic syndrome and hematologic malignanciesReem Karmali, Andrew Dalovisio, Jeffrey A Borgia, et al.
Amyloid : the International Journal of Experimental and Clinical Investigation : the Official Journal of the International Society of Amyloidosis|January 6, 2018
Treatment patterns and health care resource utilization among patients with relapsed/refractory systemic light chain amyloidosisParameswaran Hari, Huamao Mark Lin, Carl V Asche, et al.
Cytotherapy|May 21, 2022
Bispecific targeting of CD20 and CD19 increases polyfunctionality of chimeric antigen receptor T-cell products in B-cell malignanciesJoanna C Zurko, Huiqing Xu, Katherine Chaney, et al.
Journal of Geriatric Oncology|October 24, 2017
The impact of age and comorbidities on practice patterns and outcomes in patients with relapsed/refractory multiple myeloma in the era of novel therapiesParameswaran Hari, Dorothy Romanus, Katarina Luptakova, et al.
Atherosclerosis|September 18, 2012
Protective role of clusterin in preserving endothelial function in AL amyloidosisDaniel A Franco, Seth Truran, Camelia Burciu, et al.
Current Medical Research and Opinion|March 10, 2017
Disease burden of systemic light-chain amyloidosis: a systematic literature reviewHuamao Mark Lin, Xin Gao, Catherine E Cooke, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|September 2, 2015
A Phase IIb, Multicenter, Open-Label, Safety, and Efficacy Study of High-Dose, Propylene Glycol-Free Melphalan Hydrochloride for Injection (EVOMELA) for Myeloablative Conditioning in Multiple Myeloma Patients Undergoing Autologous TransplantationParameswaran Hari, Omar S Aljitawi, Carlos Arce-Lara, et al.
Pageof 26

Showing results (81-90 of 255) with videos related to

Sort By:
Pageof 26
Cytotherapy|December 31, 2017
Closed-system manufacturing of CD19 and dual-targeted CD20/19 chimeric antigen receptor T cells using the CliniMACS Prodigy device at an academic medical centerFenlu Zhu, Nirav Shah, Huiqing Xu, et al.
Contemporary Clinical Trials Communications|April 27, 2018
Rationale and design of DUAL study: Doxycycline to Upgrade response in light chain (AL) amyloidosis (DUAL): A phase 2 pilot study of a two-pronged approach of prolonged doxycycline with plasma cell-directed therapy in the treatment of AL amyloidosisAnita D'Souza, Kathryn Flynn, Saurabh Chhabra, et al.
Cytotherapy|October 12, 2015
Hydroxyethyl starch as a substitute for dextran 40 for thawing peripheral blood progenitor cell productsFenlu Zhu, Sarah Heditke, Joanne Kurtzberg, et al.
Blood Reviews|December 1, 2014
All in the family: Clueing into the link between metabolic syndrome and hematologic malignanciesReem Karmali, Andrew Dalovisio, Jeffrey A Borgia, et al.
Amyloid : the International Journal of Experimental and Clinical Investigation : the Official Journal of the International Society of Amyloidosis|January 6, 2018
Treatment patterns and health care resource utilization among patients with relapsed/refractory systemic light chain amyloidosisParameswaran Hari, Huamao Mark Lin, Carl V Asche, et al.
Cytotherapy|May 21, 2022
Bispecific targeting of CD20 and CD19 increases polyfunctionality of chimeric antigen receptor T-cell products in B-cell malignanciesJoanna C Zurko, Huiqing Xu, Katherine Chaney, et al.
Journal of Geriatric Oncology|October 24, 2017
The impact of age and comorbidities on practice patterns and outcomes in patients with relapsed/refractory multiple myeloma in the era of novel therapiesParameswaran Hari, Dorothy Romanus, Katarina Luptakova, et al.
Atherosclerosis|September 18, 2012
Protective role of clusterin in preserving endothelial function in AL amyloidosisDaniel A Franco, Seth Truran, Camelia Burciu, et al.
Current Medical Research and Opinion|March 10, 2017
Disease burden of systemic light-chain amyloidosis: a systematic literature reviewHuamao Mark Lin, Xin Gao, Catherine E Cooke, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|September 2, 2015
A Phase IIb, Multicenter, Open-Label, Safety, and Efficacy Study of High-Dose, Propylene Glycol-Free Melphalan Hydrochloride for Injection (EVOMELA) for Myeloablative Conditioning in Multiple Myeloma Patients Undergoing Autologous TransplantationParameswaran Hari, Omar S Aljitawi, Carlos Arce-Lara, et al.
Pageof 26